This company has been acquired
Ayala Pharmaceuticals (AYLA) Stock Overview
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AYLA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ayala Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$6.77 |
| 52 Week Low | US$0.36 |
| Beta | 1.99 |
| 1 Month Change | 18.49% |
| 3 Month Change | -20.06% |
| 1 Year Change | -92.53% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.65% |
Recent News & Updates
Recent updates
Ayala stock rises 12% on FDA fast track status for AL102 for desmoid tumors
Sep 27Ayala Pharma rises on positive data from phase 2/3 trial of AL102 in desmoid tumors
Sep 12Here's Why Ayala Pharmaceuticals (NASDAQ:AYLA) Must Use Its Cash Wisely
Jul 28
Here's Why We're A Bit Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Mar 19Will Ayala Pharmaceuticals (NASDAQ:AYLA) Spend Its Cash Wisely?
Sep 11We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
Jun 04Here's Why We're Not Too Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Feb 19Need To Know: Analysts Are Much More Bullish On Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenues
Nov 20
Shareholder Returns
| AYLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | 2.8% | -0.2% |
| 1Y | -92.5% | 4.0% | 20.3% |
Return vs Industry: AYLA underperformed the US Biotechs industry which returned 7.2% over the past year.
Return vs Market: AYLA underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| AYLA volatility | |
|---|---|
| AYLA Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AYLA's share price has been volatile over the past 3 months.
Volatility Over Time: AYLA's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 35 | Roni Mamluk | www.ayalapharma.com |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company’s lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors.
Ayala Pharmaceuticals, Inc. Fundamentals Summary
| AYLA fundamental statistics | |
|---|---|
| Market cap | US$7.20m |
| Earnings (TTM) | -US$38.47m |
| Revenue (TTM) | US$1.73m |
Is AYLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYLA income statement (TTM) | |
|---|---|
| Revenue | US$1.73m |
| Cost of Revenue | US$1.64m |
| Gross Profit | US$90.00k |
| Other Expenses | US$38.56m |
| Earnings | -US$38.47m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.69 |
| Gross Margin | 5.19% |
| Net Profit Margin | -2,220.08% |
| Debt/Equity Ratio | 0% |
How did AYLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 02:14 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ayala Pharmaceuticals, Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maurice Raycroft | Jefferies LLC |
| Ahu Demir | Ladenburg Thalmann & Company |
| Naureen Quibria | Maxim Group |